Introduction: Protein-bound uremic toxins such as advanced glycation end products (AGEs) are poorly cleared by conventional dialysis. Medium cut-off (MCO) membranes have been proposed to enhance their removal, but clinical evidence remains limited. Methods: In this prospective pilot study, 8 maintenance hemodialysis patients were assigned to receive a single dialysis session using either an MCO or high-flux (HF) membrane. Serum levels of N-carboxymethyllysine (CML), soluble receptor for AGEs (sRAGE), and prolactin were measured pre- and post-dialysis. Reduction ratios corrected for hemoconcentration (RRc) were compared between groups. Results: The median RRc for CML was similar between MCO (36.9%) and HF (35.6%) membranes (p = 0.686). sRAGE reduction was lower with MCO membranes (21.8% vs. 41.9%, p = 0.114), while prolactin clearance was slightly higher (58.1% vs. 50.9%, p = 0.486). No statistically significant differences were observed. Conclusion: MCO membranes did not demonstrate superior removal of protein-bound toxins compared to HF membranes in this pilot study. These findings highlight the need for alternative strategies, such as adsorption, and larger studies to define the clinical utility of MCO technology.

1.
Rosner
MH
,
Reis
T
,
Husain-Syed
F
,
Vanholder
R
,
Hutchison
C
,
Stenvinkel
P
, et al
.
Classification of uremic toxins and their role in kidney failure
.
Clin J Am Soc Nephrol
.
2021
;
16
(
12
):
1918
28
.
2.
Stinghen
AEM
,
Massy
ZA
,
Vlassara
H
,
Striker
GE
,
Boullier
A
.
Uremic toxicity of advanced glycation end products in CKD
.
J Am Soc Nephrol
.
2016
;
27
(
2
):
354
70
.
3.
Rojas
A
,
Lindner
C
,
Schneider
I
,
Gonzalez
I
,
Uribarri
J
.
The RAGE Axis: a relevant inflammatory hub in human diseases
.
Biomolecules
.
2024
;
14
(
4
):
412
.
4.
Gerdemann
A
,
Wagner
Z
,
Solf
A
,
Bahner
U
,
Heidland
A
,
Vienken
J
, et al
.
Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality
.
Nephrol Dial Transplant
.
2002
;
17
(
6
):
1045
9
.
5.
Saar-Kovrov
V
,
Zidek
W
,
Orth-Alampour
S
,
Fliser
D
,
Jankowski
V
,
Biessen
EAL
, et al
.
Reduction of protein-bound uraemic toxins in plasma of chronic renal failure patients: a systematic review
.
J Intern Med
.
2021
;
290
(
3
):
499
526
.
6.
García-Prieto
A
,
de la Flor
JC
,
Coll
E
,
Iglesias
E
,
Reque
J
,
Valga
F
.
Expanded hemodialysis: what’s up, Doc
.
Clin Kidney J
.
2023
;
16
(
7
):
1071
80
.
7.
Bergstrom
J
,
Wehle
B
.
No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis
.
Lancet
.
1987
;
329
(
8533
):
628
9
.
8.
Koç
NS
,
Yeter
H
,
Yıldırım
T
,
Erdem
Y
,
Yılmaz
R
.
Effect of medium cut-off membranes on pentosidine and N-carboxymethyl lysine levels in uncontrolled diabetic hemodialysis patients
.
Ther Apher Dial
.
2024
;
28
(
4
):
591
8
.
9.
Ramírez-Guerrero
G
,
Reis
T
,
Segovia-Hernández
B
,
Aranda
F
,
Verdugo
C
,
Pedreros-Rosales
C
, et al
.
Efficacy of HA130 hemoadsorption in removing advanced glycation end products in maintenance hemodialysis patients
.
Artif Organs
.
2025
;
49
(
5
):
900
6
.
10.
Pedreros-Rosales
C
,
Jara
A
,
Lorca
E
,
Mezzano
S
,
Pecoits-Filho
R
,
Herrera
P
.
Unveiling the clinical benefits of High-Volume Hemodiafiltration: optimizing the removal of medium-weight uremic toxins and beyond
.
Toxins
.
2023
;
15
(
9
):
531
.
You do not currently have access to this content.